Log In
BCIQ
Print this Print this
 

AzaSite Xtra (ISV-405)

  Manage Alerts
Collapse Summary General Information
Company Sun Pharmaceutical Industries Ltd.
DescriptionDurasite formulation of azithromycin (2%)
Molecular Target
Mechanism of Action 
Therapeutic ModalityMacrocycle
Latest Stage of DevelopmentPreclinical
Standard IndicationBacterial infection
Indication DetailsTreat ocular infections
Regulatory Designation
PartnerNicox S.A.;
Senju Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

5

$117.3M

$61.0M

$13.8M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today